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Erikson, 2014), affect response to PLK
inhibitors.
Other issues need further evaluation
before these ﬁndings can be translated
from bench to bedside. For example,
while PLK1 inhibitors seem to have a
manageable safety proﬁle (Gjertsen and
Schoffski, 2015), the tolerability of MEK/
PLK1i combinations remains to be
determined. In addition, identiﬁcation
of predictive biomarkers of responses to
MEK/PLK1i will be valuable. Certainly,
assessing the efﬁcacy of this combina-
tion in the context of a functional
immune system would be absolutely
necessary. Answering these questions
would provide valuable information to
advance this promising combination
and to provide rational and effective
treatment options for patients with
NRAS-mutant melanoma.
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The Broad Stroke of Hsp90 Inhibitors:
Painting over the RAF Inhibitor
Paradox
Michael J. Vido1,2 and Andrew E. Aplin1,2
The novel Hsp90 inhibitor XL888 is undergoing clinical investigation for use in
conjunction with the rapidly accelerated ﬁbrosarcoma (RAF) kinase inhibitor
vemurafenib to treat unresectable melanoma. The addition of XL888 to current
regimens may serve an additional purpose by blocking the RAF inhibitor
paradox. Such activity could reduce adverse events in patients and provide a
biomarker for the successful inhibition of Hsp90 target proteins.
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In this issue of Journal of Investigative
Dermatology, Phadke et al. (2015) report
results from a phase I dose-escalation
study of XL888, a novel Hsp90 inhibitor,
in combination with the rapidly
accelerated ﬁbrosarcoma (RAF) kinase
inhibitor vemurafenib in patients with
unresectable BRAF-mutant melanoma
(NCT01657591). Fifty percent of patients
with melanomas harbor an activating
valine to glutamic acid substitution
(V600E) in the serine/threonine kinase
BRAF that signals through the extracel-
lular signal-regulated kinase 1/2 (ERK1/2)
pathway. Despite initial efﬁcacy, BRAF
inhibitor monotherapy and newer BRAF/
mitogen-activated protein kinase kinase
(MEK) inhibitor combination therapy
inevitably yield to therapy resistance.
Mechanisms driving resistance include
the acquisition of NRAS mutations,
expression of BRAF splice variants,
ampliﬁcation of BRAF V600E, and the
upregulation of receptor tyrosine kinases
leading to ERK and AKT pathway activa-
tion (Hartsough et al., 2014). The use of
Hsp90 inhibitors in conjunction with
vemurafenib is being pursued to pro-
vide a broad stroke of inhibition against
these resistant pathways. Here the authors
report a second potential clinical beneﬁt,
namely, the reduction of paradoxical
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ERK1/2 activation that occurs as a result
of treatment with ﬁrst-generation RAF
inhibitors.
In addition to limited durable treatment
responses, vemurafenib and other ﬁrst-
generation RAF inhibitors display para-
doxically activating ERK1/2 signaling in
BRAF wild-type cells. As reviewed by
Gibney et al. (2013) this activation occurs
via enhanced dimerization of RAF mono-
mers, either through the relief of BRAF
autoinhibition or through conformational
changes that stabilize protein–protein
interaction when a single RAF monomer
is bound to an inhibitor. Ultimately,
dimerization with and activation of
CRAF enables phosphorylation of down-
stream MEK and ERK1/2 targets
(Poulikakos et al., 2010). In patients, this
paradoxical activation causes the genera-
tion of a number of hyperproliferative
cutaneous lesions, including squamous
cell carcinomas, keratocanthomas, papil-
lary lesions, and verrucous keratosis, as
well as nevi and new primary melanomas.
These lesions have been treated by
excision and no patients with metastases
have been encountered; however, the
potential for malignancies at other less-
accessible locations remains a concern.
The observation that rare cases of colonic
adenomas, gastric polyps, and a single
case of myelomonocytic leukemia have
been encountered during RAF inhibition
highlights the potential for paradoxical
ERK1/2 activation in other tissues (Gibney
et al., 2013).
The Hsp90 chaperone protein binds to
target proteins to support refolding and
thereby can promote cell survival during
times of stress. Many proteins integral
to melanoma progression and therapy
resistance represent Hsp90 “clients”,
including mutant BRAF (but not wild-
type BRAF), CRAF, COT, PDGFR, IGF1R,
and AKT; it is through these interactions
that Hsp90 exhibits pro-tumorigenic
activity (Grbovic et al., 2006). First-
generation Hsp90 inhibitors derived from
the natural geldanamycin product stu-
died within the last decade have demon-
strated promising preclinical results
but have ultimately failed to garner the
Food and Drug Administration (FDA)
approval. In human melanoma cell lines,
the Hsp90 inhibitor 17-allylamino-
17-demethoxygeldanamycin (17-AAG)
induced ubiquitination and proteasome-
mediated degradation of BRAF V600E
and caused BRAF V600E degradation
and growth inhibition in SK-MEL-28
xenografts (Grbovic et al., 2006). 17-
AAG progressed to phase I and phase II
clinical trials and was implemented at the
highest tolerated dose (450mgm−2
intravenous once weekly). Signiﬁcant
increases in Hsp70 protein levels at a
posttreatment biopsy (median 44 hours)
compared with pretreatment biopsy indi-
cated successful Hsp90 inhibition; how-
ever, BRAF and CRAF levels remained
unchanged, as did phospho-ERK1/2, a
measurement of ERK1/2 pathway activity
(Solit et al., 2008). These ﬁndings
contrasted with the phase I results that
showed reductions in client proteins at
24 hours (Banerji et al., 2005). Taken
together with the measured increase in
Hsp70 in the phase II studies, this ﬁnding
suggests that the biologic effect of 17-
AAG was short lived and that more
potent Hsp90 inhibitors capable of
chronic dosing could improve treatment
efﬁcacy.
The FDA approval of targeted thera-
pies with diverse resistance mechan-
isms has rekindled interest in Hsp90
inhibitors. 17-AAG required bioreduc-
tion to a hydroquinone 17-AAGH2 to
elicit its full effects, and the expression
of P-glycoprotein or loss of NAD(P)H
dehydrogenase, quinone 1 (NQO1),
could prevent this metabolic event.
XL888 is a novel non-benzoquinone,
ATP-competitive inhibitor of Hsp90
(Catalanotti and Solit, 2012). Inhibition
of Hsp90 with XL888 leads to proteo-
lytic degradation of these proteins in
multiple melanoma models. Preclinical
data have shown that such inhibitors
can effectively block ERK1/2 signaling
in RAF inhibitor–resistant cell lines
(Paraiso et al., 2012) and in combina-
tion with vemurafenib can delay the
emergence of resistance in xenograft
models (Smyth et al., 2014).
Whether XL888 will be hampered by
the same limitations as 17-AAG remains
to be seen. This ﬁrst report of phase I
results provides some optimism regard-
ing the ability of XL888 to successfully
destabilize Hsp90 client proteins.
Following 24 weeks of vemurafenib
and XL888 treatment (35, 45, 90, and
135mg twice per week by mouth for
four cohorts, respectively) the authors
report an overall reduction in the
number of hyperproliferative/neoplastic
skin lesions. Notably, the cohort treated
with the highest concentration of XL888
experienced two verruca vulgaris lesions
among six patients and no squamous cell
carcinomas, keratocanthomas, or new
primary melanomas. In mutant NRAS/
wild-type BRAF mutant cell lines, XL888
is capable of reversing the paradoxical
activation of ERK1/2 induced by vemur-
afenib at concentrations higher than
100 nM. Mechanistically, Phadke et al.
show that treatment with 300 nM XL888
reduces expression of CRAF, a critical
mediator of the paradox effect (Poulikakos
et al., 2010; Gibney et al., 2013).
Inhibition of the paradox effect is
undoubtedly important in the context of
RAF inhibition. In addition to requiring
an increased number of follow-up pro-
cedures to remove cutaneous lesions, the
activation of ERK1/2 signaling can also
lead to other non-cutaneous lesions that
are difﬁcult to identify (Gibney et al.,
2013). FDA-approved RAF and MEK
inhibitor combination therapies now
provide this beneﬁt, and it remains to
be seen whether XL888 therapy achieves
this aim in a statistically signiﬁcant
fashion. Perhaps more critically, these
ﬁndings point to the possibility that the
reduction in CRAF levels could repre-
sent a biomarker for successful Hsp90
therapy in conjunction with RAF inhibi-
tion. Despite the common use of
Clinical Implications
● The RAF inhibitors paradoxically cause hyperplastic lesions in melanoma
patients.
● Treatment with Hsp90 inhibitors may block this event and reduce its
frequency.
● Reduction of paradoxical signaling may serve as a biomarker for
successful Hsp90 inhibition.
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increased Hsp70 expression as a surro-
gate for successful Hsp90 inhibition,
patients receiving Hsp90 inhibition often
demonstrate varied expression levels
compared with Hsp70 (Catalanotti and
Solit, 2012), and, as observed with
17-AAG, client protein, destabilization
and treatment effects may not correlate
with Hsp70 induction (Solit et al., 2008).
As investigation continues with XL888,
validation of such a biomarker may
provide a more robust measure of
clinically relevant Hsp90 inhibition and
favorable patient response.
Ultimately, additional data are
needed to understand whether XL888
is eliciting the desired effect on Hsp90
client proteins. Preclinical data point to
the possibility that XL888 can inhibit the
diverse modes of resistance encountered
with RAF inhibition and that combina-
tion therapy with vemurafenib can delay
the time to relapse. Further testing
of XL888 efﬁcacy will come
in the form of pre/posttreatment biopsies
that directly measure the effects of
Hsp90 inhibition on client protein
expression and ERK1/2 pathway activa-
tion. This phase I trial was insufﬁciently
powered to demonstrate changes in
hyperproliferative lesions that are statis-
tically useful. However, the promising
results presented in this article suggest
that there is indeed an inhibitory effect.
Quantifying these lesions will remain a
focus in an upcoming phase II clinical
trial testing XL888 in conjunction with
combined RAF and MEK inhibitors.
Only with this added clinical data will
XL888 be spared the fate of 17-AAG and
other ﬁrst-generation Hsp90 inhibitors.
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